13F Holdings
中文EN

BJDX Bluejay Diagnostics, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1704287 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-12.2%
TTM EPS YoY119.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-138.1%
ROA-107.8%
ROIC (approx.)-1,839.1%
Asset turnover—

Leverage & solvency

Liabilities / assets20.6%
Debt / equity0.00x
Current ratio3.91x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-16.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue———$249,040—
Cost of revenue———$200,129—
Gross profit———$48,911—
R&D expense$3.05M$3.47M$5.71M$4.15M$1.15M
SG&A expense$3.91M$3.69M$4.31M$451,421$1.79M
Operating income-$6.95M-$7.17M-$10.31M-$9.32M-$3.23M
Interest expense$839$823,028——$6,360
Net income-$6.85M-$7.72M-$9.95M-$9.30M-$3.49M
EBITDA-$6.88M-$7.09M-$9.66M-$9.16M-$3.08M
EPS (basic)-15.25-456.75-3,631.48-9.22-0.41
EPS (diluted)-15.25-456.75-3,631.48-9.22-0.41
Weighted avg. shares (diluted)449,04345,8482,7411.01M8.52M
Banking
Net interest income————-$367,459
Balance sheet
Cash & equivalents$5.16M$4.30M$2.21M$10.11M$19.05M
Current assets$5.46M$4.90M$3.22M$11.79M$20.66M
PP&E, net$1.53M$1.51M$1.29M$1.23M$337,366
Total assets$7.12M$6.66M$4.87M$13.52M$21.02M
Current liabilities$1.12M$810,368$1.77M$1.64M$637,162
Total liabilities$1.14M$927,924$1.97M$1.98M$637,162
Shareholders' equity$5.98M$5.73M$2.89M$11.54M$20.38M
Shares outstanding151,133138,5033,0981.01M20.11M
Cash flow statement
Operating cash flow-$6.05M-$7.82M-$8.31M-$7.74M-$4.37M
Capital expenditure$173,735$306,783$704,166$1.20M$23,947
Free cash flow-$6.23M-$8.13M-$9.02M-$8.94M-$4.39M
Investing cash flow-$173,735-$306,783-$704,166-$1.20M-$23,947
Financing cash flow$7.09M$10.22M$1.11M$8,075$22.53M
Depreciation & amortization$74,182$75,618$648,708$156,598$145,719
Stock-based compensation$6$20,094$189,245$433,004$68,458

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.